Table of Content

1. U.S. Tardive Dyskinesia Treatment Market – Methodology and Scope
1.1. Research Methodology
1.2. Scope of the Report
2. U.S. Tardive Dyskinesia Treatment Market – Definition and Overview
3. U.S. Tardive Dyskinesia Treatment Market – Executive Summary
3.1. Market Snippet by Drug
3.2. Market Snippet by Distribution Channel
3.3. Market Snippet by Region
4. U.S. Tardive Dyskinesia Treatment Market – Market Dynamics
4.1. Market Drivers
4.1.1. Increasing clinical approvals
4.1.2. Prolonged use of antipsychotic drugs by patients
4.1.3. An increase in the aging population
4.2. Market Restraints
4.2.1. Side effects associated with the drugs
4.2.2. Lack of awareness about the disorder
4.3. Market Opportunity
4.4. Emerging Countries
4.5. The development of novel therapies
4.6. Impact Analysis
5. U.S. Tardive Dyskinesia Treatment Market – Industry Factors
5.1. Porter’s Five Force Analysis
5.2. Regulatory Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Patent Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
5.8. Epidemiology Analysis
6. U.S. Tardive Dyskinesia Treatment Market – COVID-19
6.1. Analysis of COVID-19 on the Market*
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario After COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. U.S. Tardive Dyskinesia Treatment Market – By Drug
7.1. Introduction
7.1.1. Market Size and Y-o-Y Growth Analysis (%), By Drug
7.1.2. Market Attractiveness Index, By Drug
7.2. Valbenazine*
7.2.1. Introduction
7.2.2. Market Size, 2022-2031 and Y-o-Y Growth (%), 2023-2031
7.3. Tetrabenazine
7.4. Deutetrabenazine
7.5. Amantadine
7.6. Clonazepam
7.7. Others
8. U.S. Tardive Dyskinesia Treatment Market – By Distribution Channel
8.1. Introduction
8.1.1. Market Size and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
9. Hospital and Speciality Pharmacies*
9.1. Introduction
9.2. Market Size, 2022-2031 and Y-o-Y Growth (%), 2023-2031
10. Retail Pharmacies
11. Others
12. U.S. Tardive Dyskinesia Treatment Market – Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. U.S. Tardive Dyskinesia Treatment Market – Company Profiles
13.1. Teva Pharmaceutical Industries Ltd*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Neurocrine Biosciences, Inc.
13.3. Lupin Limited
13.4. Accord Healthcare, Inc.
13.5. Mitsubishi Corporation
13.6. Dr. Reddy’s Laboratories Limited
13.7. BIONPHARMA INC.
13.8. Slate Run Pharmaceuticals
13.9. Aurobindo Pharma Limited
13.10. Apotex Inc.
14. U.S. Tardive Dyskinesia Treatment Market – DataM
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us